Chromosomal structural variations during progression of a prostate epithelial cell line to a malignant metastatic state inactivate the NF2, NIPSNAP1, UGT2B17, and LPIN2 genes

Cancer Biology and Therapy

Volumn 14, Issue 9, 2013, Pages 840-852

  Malhotra, Ankit ^a   Shibata, Yoshiyuki ^a   Hall, Ira M ^a   Dutta, Anindya ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

AbCNV; Complex rearrangements; High throughput sequencing; HYDRA; Metastasis; NF2; NIPSNAP1; Prostate cancer

Indexed keywords

ANDROSTANOLONE; MERLIN; PHOSPHATIDATE PHOSPHATASE; GLUCURONOSYLTRANSFERASE; LPIN2 PROTEIN, HUMAN; NUCLEAR PROTEIN; UGT2B17 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER CELL; CANCER GROWTH; CELL LINE; CHROMOSOME STRUCTURE; COPY NUMBER VARIATION; EPITHELIUM CELL; GENE; GENOME; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 18; INFLAMMATION; LIPID METABOLISM; LPIN2 GENE; MALE; METASTASIS; NF2 GENE; NIPSNAP1 GENE; ONCOGENE; PROSTATE CANCER; PROSTATE EPITHELIAL CELL LINE; STEM CELL; TUMOR SUPPRESSOR GENE; UGT2B17 GENE; CARCINOGENESIS; GENETIC VARIABILITY; GENETICS; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR INVASION;

CARCINOGENESIS; CELL LINE, TUMOR; EPITHELIAL CELLS; GENES, TUMOR SUPPRESSOR; GENOMIC STRUCTURAL VARIATION; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS;

EID: 84883366463     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.25329     Document Type: Article

References (44)

1. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003; 138:819-30; PMID:12755554; http://dx.doi.org/10.7326/0003- 4819-138-10-200305200-00010
2. Campbell PJ, Stephens PJ, Pleasance ED, O'Meara S, Li H, Santarius T, et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet 2008; 40:722-9; PMID:18438408; http://dx.doi.org/10.1038/ng.128
3. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361:1058-66; PMID:19657110; http:// dx.doi.org/10.1056/ NEJMoa0903840
4. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010; 463:184-90; PMID:20016488; http:// dx.doi.org/10.1038/nature08629
5. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009; 462:1005-10; PMID:20033038; http:// dx.doi.org/10.1038/nature08645
6. Hampton OA, Den Hollander P, Miller CA, Delgado DA, Li J, Coarfa C, et al. A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome. Genome Res 2009; 19:167-77; PMID:19056696; http://dx.doi.org/10.1101/ gr.080259.108
7. Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA, et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 2009; 11:804-11; PMID:19649210
8. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010; 463:191-6; PMID:20016485; http://dx.doi.org/10.1038/ nature08658
9. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol 2011; 29:3659-68; PMID:21859993; http://dx.doi.org/10. 1200/JCO.2011.35.1916
10. Wang XS, Shankar S, Dhanasekaran SM, Ateeq B, Sasaki AT, Jing X, Robinson D, Cao Q, Prensner JR, Yocum AK, et al. Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov 2011; 1:35-43; PMID:22140652; http://dx.doi.org/10.1158/2159-8274.CD-10-0022
11. Wu C, Wyatt AW, Lapuk AV, McPherson A, McConeghy BJ, Bell RH, et al. Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol 2012; 227:53-61; PMID:22294438; http://dx.doi.org/10.1002/path.3987
12. Webber MM, Quader ST, Kleinman HK, Bello-DeOcampo D, Storto PD, Bice G, et al. Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. Prostate 2001; 47:1-13; PMID:11304724; http://dx.doi.org/10. 1002/ pros.1041
13. Quinlan AR, Clark RA, Sokolova S, Leibowitz ML, Zhang Y, Hurles ME, et al. Genome-wide mapping and assembly of structural variant breakpoints in the mouse genome. Genome Res 2010; 20:623-35; PMID:20308636; http://dx.doi.org/10. 1101/ gr.102970.109
14. Hercus C. Unpublished, http://www.novocraft.com.
15. Chiang DY, Getz G, Jaffe DB, O'Kelly MJ, Zhao X, Carter SL, et al. High-resolution mapping of copynumber alterations with massively parallel sequencing. Nat Methods 2009; 6:99-103; PMID:19043412; http://dx.doi.org/10. 1038/nmeth.1276
16. Quinlan A.
17. Yoon S, Xuan Z, Makarov V, Ye K, Sebat J. Sensitive and accurate detection of copy number variants using read depth of coverage. Genome Res 2009; 19:1586-92; PMID:19657104; http://dx.doi.org/10.1101/ gr.092981.109
18. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, et al.; 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 2010; 467:1061-73; PMID:20981092; http://dx.doi.org/10.1038/ nature09534
19. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Circos: an information aesthetic for comparative genomics. Genome Res 2009; 19:1639-45; PMID:19541911; http://dx.doi.org/10.1101/gr.092759.109
20. Reimand J, Kull M, Peterson H, Hansen J, Vilo J. g:Profiler - a web-based toolset for functional profiling of gene lists from large-scale experiments. Nucleic Acids Res 2007; 35(Web Server issue):W193-200; PMID:17478515; http://dx.doi.org/10.1093/nar/ gkm226
21. Reimand J, Arak T, Vilo J. g:Profiler - a web server for functional interpretation of gene lists (2011 update). Nucleic Acids Res 2011; 39(Web Server issue):W307-15; PMID:21646343; http://dx.doi.org/10.1093/nar/gkr378
22. Xie C, Tammi MT. CNV-seq, a new method to detect copy number variation using high-throughput sequencing. BMC Bioinformatics 2009; 10:80; PMID:19267900; http://dx.doi.org/10.1186/1471-2105-10-80
23. Daines B, Wang H, Li Y, Han Y, Gibbs R, Chen R. High-throughput multiplex sequencing to discover copy number variants in Drosophila. Genetics 2009; 182:935-41; PMID:19528327; http://dx.doi.org/10.1534/genetics.109.103218
24. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006; 66:3396-400; PMID:16585160; http://dx.doi.org/10.1158/0008- 5472.CAN-06-0168
25. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, et al. TMPRSS2:ERG fusionassociated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006; 66:8337-41; PMID:16951139; http://dx.doi.org/10.1158/0008-5472.CAN-06-1482
26. Rubin MA, Chinnaiyan AM. Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer. Lab Invest 2006; 86:1099-102; PMID:16983328
27. Hanauer DA, Rhodes DR, Sinha-Kumar C, Chinnaiyan AM. Bioinformatics approaches in the study of cancer. Curr Mol Med 2007; 7:133-41; PMID:17311538; http://dx.doi.org/10.2174/156652407779940431
28. Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, van de Rijn M, et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Modern pathology: an official journal of the United States and Canadian Academy of Pathology. Inc 2007; 20:467-73
29. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009; 458:97-101; PMID:19136943; http://dx.doi.org/10.1038/ nature07638
30. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 2010; 16:793-8; PMID:20526349; http://dx.doi.org/10.1038/nm.2166
31. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470:214-20; PMID:21307934; http://dx.doi.org/10.1038/nature09744
32. Zhang Y, Gong M, Yuan H, Park HG, Frierson HF, Li H. Chimeric transcript generated by cissplicing of adjacent genes regulates prostate cancer cell proliferation. Cancer Discov 2012; 2:598-607; PMID:22719019; http://dx.doi.org/10.1158/2159-8290.CD-12-0042
33. Cui Y, Ying Y, van Hasselt A, Ng KM, Yu J, Zhang Q, et al. OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One 2008; 3:e2990; PMID:18714356; http://dx.doi.org/10.1371/journal. pone.0002990
34. Kawana Y, Ichikawa T, Suzuki H, Ueda T, Komiya A, Ichikawa Y, et al. Loss of heterozygosity at 7q31.1 and 12p13-12 in advanced prostate cancer. Prostate 2002; 53:60-4; PMID:12210480; http://dx.doi.org/10.1002/ pros.10131
35. Chêne L, Giroud C, Desgrandchamps F, Boccon-Gibod L, Cussenot O, Berthon P, et al. Extensive analysis of the 7q31 region in human prostate tumors supports TES as the best candidate tumor suppressor gene. Int J Cancer 2004; 111:798-804; PMID:15252854; http://dx.doi.org/10.1002/ijc.20337
36. Capozza F, Williams TM, Schubert W, McClain S, Bouzahzah B, Sotgia F, et al. Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. Am J Pathol 2003; 162:2029-39; PMID:12759258; http://dx.doi.org/10.1016/S0002-9440(10)64335-0
37. Fiucci G, Ravid D, Reich R, Liscovitch M. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 2002; 21:2365-75; PMID:11948420; http://dx.doi.org/10. 1038/sj.onc.1205300
38. Horiguchi A, Zheng R, Shen R, Nanus DM. Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells. Prostate 2008; 68:975-84; PMID:18361411; http://dx.doi.org/10.1002/pros.20760
39. Hanemann CO. Magic but treatable? Tumours due to loss of merlin. Brain 2008; 131:606-15; PMID:17940085; http://dx.doi.org/10.1093/brain/ awm249
40. Schoeber JPH, Topala CN, Lee KP, Lambers TT, Ricard G, van der Kemp AWCM, et al. Identification of Nipsnap1 as a novel auxiliary protein inhibiting TRPV6 activity. Pflugers Arch 2008; 457:91-101; PMID:18392847; http://dx.doi.org/10. 1007/s00424-008-0494-5
41. Lehen'kyi V, Flourakis M, Skryma R, Prevarskaya N. TRPV6 channel controls prostate cancer cell proliferation via Ca(2+)/NFAT-dependent pathways. Oncogene 2007; 26:7380-5; PMID:17533368; http://dx.doi.org/10.1038/sj.onc.1210545
42. Barbier O, Bélanger A. Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate. Best Pract Res Clin Endocrinol Metab 2008; 22:259-70; PMID:18471784; http://dx.doi.org/10.1016/j. beem.2008.01.001
43. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003; 4:446-56; PMID:12778124; http://dx.doi.org/10.1038/ nrm1128
44. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for Rho-Associated kinase in the transcellular invasion of tumor cells. Nat Med 1999; 5:221-5; PMID:9930872; http://dx.doi.org/10.1038/5587